Ken Griffin
MLTX icon

Ken Griffin’s MoonLake Immunotherapeutics MLTX Stock Holding History

Ken Griffin’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.7M Buy
1,323,728
+942,838
+248% +$15.6M ﹤0.01% 2077
2025
Q4 		$5.02M Buy
380,890
+331,556
+672% +$3.91M ﹤0.01% 4283
2025
Q3 		$354K Sell
49,334
-1,624,707
-97% -$84.7M ﹤0.01% 9970
2025
Q2 		$79M Buy
1,674,041
+195,406
+13% +$7.96M 0.01% 915
2025
Q1 		$57.8M Sell
1,478,635
-708,231
-32% -$30.5M 0.01% 1045
2024
Q4 		$118M Sell
2,186,866
-136,105
-6% -$6.95M 0.02% 651
2024
Q3 		$117M Buy
2,322,971
+57,276
+3% +$2.68M 0.02% 609
2024
Q2 		$99.6M Sell
2,265,695
-43,738
-2% -$1.85M 0.02% 686
2024
Q1 		$116M Buy
2,309,433
+300,773
+15% +$16.3M 0.02% 616
2023
Q4 		$121M Sell
2,008,660
-25,736
-1% -$1.33M 0.02% 577
2023
Q3 		$116M Buy
2,034,396
+13,788
+0.7% +$761K 0.02% 553
2023
Q2 		$103M Sell
2,020,608
-902,830
-31% -$24.3M 0.02% 598
2023
Q1 		$62.5M Buy
2,923,438
+37,346
+1% +$628K 0.01% 906
2022
Q4 		$30.3M Buy
2,886,092
+200,155
+7% +$1.78M 0.01% 1545
2022
Q3 		$21.4M Sell
2,685,937
-16,724
-0.6% -$118K ﹤0.01% 1806
2022
Q2 		$13.9M Buy
2,702,661
+2,003,765
+287% +$12.6M ﹤0.01% 2267
2022
Q1 		$7.76M Buy
698,896
+12,959
+2% +$129K ﹤0.01% 3381
2021
Q4 		$6.6M Hold
685,937
– – ﹤0.01% 3817
2021
Q3 		$6.77M Sell
685,937
-5,794
-0.8% -$57.8K ﹤0.01% 3742
2021
Q2 		$7.15M Sell
691,731
-1,636
-0.2% -$16.6K ﹤0.01% 3703
2021
Q1 		$7.07M Buy
693,367
+6,289
+0.9% +$69.3K ﹤0.01% 3558
2020
Q4 		$7.44M Buy
+687,078
New +$7.29M ﹤0.01% 3051

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ken Griffin's MLTX Position: Q1 2026 in Review

Ken Griffin increased its MoonLake Immunotherapeutics (MLTX) stake by 248% in Q1 2026, buying an estimated $15.6M and bringing the position to 1,323,728 shares worth $24.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2077.

Ken Griffin first reported a position in MLTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $121M in Q4 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Ken Griffin held 1,323,728 shares of MoonLake Immunotherapeutics worth $24.7M as of Q1 2026.
  • Ken Griffin bought 942,838 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $15.6M.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #2077 holding.
  • Ken Griffin first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 22 quarters since.
  • Ken Griffin's MoonLake Immunotherapeutics position peaked at $121M in Q4 2023.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.